In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein.

In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein.

Publication date: Mar 25, 2024

The novel coronavirus disease 2019 has stimulated the rapid development of new biological therapeutics to inhibit SARS-CoV-2 infection; however, this remains a challenging task. In a previous study using structural analysis, we revealed that human cyclophilin A inhibits the entry of SARS-CoV-2 into host cells by interfering with the interaction of the receptor-binding domain of the spike protein with angiotensin-converting enzyme 2 on the host cell surface, highlighting its potential for antiviral therapy. For a comprehensive experimental validation, in this study, we verified the antiviral effects of human cyclophilin A against SARS-CoV-2, including its variants, using in vitro assays and experiments on an in vivo mouse model. Human cyclophilin A demonstrated a highly effective antiviral effect, with an 85% survival rate upon SARS-CoV-2 infection. It also reduced viral titers, inflammation in the lungs and brain, and cytokine release in the serum, suggesting a controlled immune response and potentially faster recovery. Overall, our study provides insights into the potential of human cyclophilin A as a therapeutic agent against SARS-CoV-2, which should guide future clinical trials that might provide an additional therapeutic option for patients.

Concepts Keywords
Antiviral Antiviral
Coronavirus COVID-19
Effective Cyclophilin A
Serum Cytokine storm
Therapy Inflammation
SARS-CoV-2
Spike protein
Therapeutic

Semantics

Type Source Name
disease MESH coronavirus disease 2019
pathway REACTOME SARS-CoV-2 Infection
disease IDO host
drug DRUGBANK Angiotensin II
disease VO effective
disease MESH inflammation
disease IDO immune response
disease MESH Cytokine storm

Original Article

(Visited 1 times, 1 visits today)